(This document is a summary English translation of the original Japanese document. If there are any discrepancies between this document and the original Japanese document, the original Japanese document prevails.)

February 26, 2025

Company name: ROHTO Pharmaceutical Co., Ltd.
Representative: Masashi Sugimoto, President and COO
(Code: 4527 TSE Prime)
Contact: Masaya Saito, Vice President and CFO
(TEL:06-6758-8223)

Notice Regarding Repurchase of Shares through an Off-Auction Share Repurchase Transaction (ToSTNeT-3) (Repurchase of Shares pursuant to Provision of Articles of Incorporation in accordance with Article 459, Paragraph 1 of the Companies Act)

ROHTO PHARMACEUTICAL CO., LTD. (the "Company") hereby announces that the pursuant to a resolution of the Board of Directors as of February 26, 2025, the Company has resolved to repurchase its own shares pursuant to provision of the Articles of Incorporation in accordance with Article 459, Paragraph 1 of the Companies Act, and that the specific repurchase method has been decided as described below.

1. Method of repurchase

The repurchase shall be at today's closing price (February 26, 2025) of JPY 2,299.5 through an off-auction share repurchase transaction conducted via the Off-Auction Own Share Repurchase Trading system of the Tokyo Stock Exchange (ToSTNeT-3) at 8:45 a.m. (Tokyo time) on February 27, 2025 (no other changes to the transaction system or transaction time shall be made). This repurchase order shall only be valid at such transaction time stated above.

2. Details of the matters related to repurchase

(1)	Class of Shares to be Repurchased	Common stock
(2)	Total Number of Shares which may be Repurchased	2,174,300 shares
(3)	Total Repurchase Price of Shares	¥4,999,802,850
(4)	Announcement of the results of the repurchase	The results of the repurchase will be announced after the transaction ends at 8:45 a.m. (Tokyo

Note: This press release is intended as general information regarding ROHTO Pharmaceutical Co., Ltd.'s determination of matters pertaining to repurchase of its own shares. This press release does not constitute an offer to purchase or subscribe for, or the solicitation of an offer to purchase or subscribe for any securities issued by the Company (the "Securities") in the United States or in any jurisdiction in which such offer or solicitation is unlawful. In particular, the Securities have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any relevant securities laws of any state or other jurisdictions of the United States, and any such Securities may not be offered or sold within the United States, absent registration or an exemption from registration under the Securities Act, and in compliance with any applicable state or local securities laws; any public offering of securities to be made in the United States will be made by means of a prospectus that may be obtained from the Company. No public offering of the Securities will be made in the United States.

time) on February 27, 2025.

(Note1) The purchase order may not be implemented, in whole or in part, depending on market conditions and other factors.

(Note2) The purchase will be made with a sell order equivalent to the number of shares planned to be acquired.

(Note3) If the number of shares acquired through this offer is fewer than the total number of shares to be acquired as stated above, the Company intends to continue to repurchase its own shares as necessary during the period from February 27, 2025 to April 30, 2025, taking market conditions, regulations, etc., into consideration.

(Reference)

Resolution of the Board of Directors as of February 26, 2025 regarding Repurchase of Shares

- Class of Shares to be Repurchased	Common stock
- Total Number of Shares which may be Repurchased	Up to 2,430,000 shares (approximately 1.07% of the total issued shares as of December 31, 2024 (excluding treasury stock))
- Total Repurchase Price of Shares	Up to ¥5 billion
- Repurchase Period	From February 27, 2025 to April 30, 2025
- Repurchase Method	Market purchase (including an off-auction purchase transaction) at the Tokyo Stock Exchange

Note: This press release is intended as general information regarding ROHTO Pharmaceutical Co., Ltd.'s determination of matters pertaining to repurchase of its own shares. This press release does not constitute an offer to purchase or subscribe for, or the solicitation of an offer to purchase or subscribe for any securities issued by the Company (the "Securities") in the United States or in any jurisdiction in which such offer or solicitation is unlawful. In particular, the Securities have not been, and will not be, registered under the U.S. Securities Act of 1933, as amended (the "Securities Act") or any relevant securities laws of any state or other jurisdictions of the United States, and any such Securities may not be offered or sold within the United States, absent registration or an exemption from registration under the Securities Act, and in compliance with any applicable state or local securities laws; any public offering of securities to be made in the United States will be made by means of a prospectus that may be obtained from the Company. No public offering of the Securities will be made in the United States.